Skip to content

Efficacy of Two Vaginal Solutions in Preoperative Use

Efficacy Comparison of Two Vaginal Solutions for Preoperative Use in Candidate Women for Vaginal Surgeries

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03014778
Enrollment
70
Registered
2017-01-09
Start date
2017-01-01
Completion date
2019-03-31
Last updated
2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Surgeries

Brief summary

This study is necessary in order to provide proof the effectiveness of Chlorhexidine gluconate and its safety.

Detailed description

It is well known from the literature that the use of Povidone-iodone based solution for vaginal preparation before surgery is fraught with side effects and sensitivity, and often does not provide sufficient eradication of colonies of pathogens from the operation field. It is also known that Chlorhexidine gluconate in low concentration provides a better result and does not cause side effects more than Povidone-iodone, but the chlorhexidine is still not approved for washing the mucous membranes. This study is necessary in order to provide proof of its effectiveness and safety.

Interventions

DRUGThe Chlorhexidine gluconate 0.05%

Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%

Washing vagina pre- operatively with 10% Povidone iodine

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Patients over the age of 18 2. Candidates for surgery (TOT- Trans Obturator Tape, cystoscopy, the introduction / removal of the stent the ureter, ureteroscopy), local or general anesthesia.

Exclusion criteria

1. A pregnant woman or post-partum. 2. A woman with known sensitivity to iodine, povidon or chlorhexidine. 3. Previous pelvic surgeries within three months from the surgery planned. 4. Patients taking antibiotics within one month from the surgery planned. 5. Immunological failure patients. 6. Patient unwilling to participate in the study. 7. Patients who require the appointment of a guardian condition 8. Women assigned to undergo a regular cystoscopy (no further action).

Design outcomes

Primary

MeasureTime frame
Changing in the number of colonies that grew at every stageBefore the washing, 10 minutes after washing, 30 minutes after washing.

Secondary

MeasureTime frame
Signs of local irritation mucosa after each bathing preparations by looking at the mucosa, at the end of the clinical assessment.30 minutes after washing.
The appearance of signs of systemic allergic reactions after each bathing by looking at the mucosa, at the end of the clinical assessment.Before the washing, 10 minutes after washing, 30 minutes after washing.

Countries

Israel

Contacts

Primary ContactSharon Tzemah, MD
sharon_tze1@clalit.org.il97252-6678244
Backup ContactMichael Gross, MD
michael_gr1@clalit.org.il97254-6676778

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026